To get in touch, especially for new requests, our preferred contact is via email: firstname.lastname@example.org. This email address reaches both the team members below and Victoria Hughes (Senior Trials Unit and R&D Manager). This is the route through which new requests are discussed and assigned. Given that our working pattern for Papworth trials is spread across different days, it may take up to one week for us to discuss any proposals and respond. If you are contacting us regarding a general consultation, again it may take up to one week for us to respond. If you wish to discuss a potential future grant application, please contact Leanne Hurren (email@example.com) to book a slot in the ‘protocol and grant development worshops’ where a wider PTUC team can discuss this in conjunction with the Stats team.
I am an MRC Investigator in the clinical trials methodology group, part of the Design and Analysis of Randomised Trials (DART) theme.
My research aims to improve clinical trial design through the development of innovative methods that lie in the intersection between optimisation, machine learning and statistics. These methods may result in efficiency gains (i.e. smaller or faster trials) but face several practical barriers (e.g. a high computational cost) to be widely adopted. These innovations include patient-centric trials - i.e. those having an explicit goal of assigning more trial participants to superior treatments (e.g. an efficacious vaccine). My proposed programme includes four main objectives: 1) developing computationally easy to implement innovative trial designs, 2) improving analysis methods of optimal, patient-centric adaptive trials (estimation and testing); 3) designing innovative trial designs in response of specific emerging challenges (including using adaptive experiments to enhance and personalise m-health apps) and 4) promoting update and appropriate application of these novel designs in practice. For this last point 4) my collaboration with Papworth is fundamental and a main goal if my involvement in PTUC is to identify opportunities for the appropriate application of innovative designs and develop them into successful trials.
I am involved in two national trials that include an adaptive or innovative element. These are NIHR funded: The PIPAH trial (Positioning Imatinib for Pulmonary Arterial Hypertension) and The NOTACS trial (Nasal High-Flow Oxygen Therapy After Cardiac Surgery).
Other selected studies: MRC grant with Mark Toshner (Stratified adaptive therapeutic studies in pulmonary arterial hypertension caused by mutations in BMPR2), Rfpb study with Tim Quinell, Intelligent Stethtoscope, Prodose, HOPE.
Other responsibilities: training sessions, general managing of the team, PTUC meetings, open surgeries, link with BSU, UK network of CTUs meetings.
I am a Research Associate in the MRC Biostatistics Unit, in the Design and Analysis of Randomised Trials group with the statisticians in the PTUC.
My research aims are to improve designs for clinical trials and to apply these improved designs in real-life trials. For me, “improvement” could mean a number of things, including reducing the number of participants required or creating a design that caters to an unmet need of investigators. I also have experience of clinical trials that evaluate multiple treatments in a single trial, known as multi-arm trials.
While I’m interested in all types of adaptive design, my particular expertise is in adaptive designs that use a binary (response/no response) primary outcome. For this type of design, I have developed an approach that greatly reduces the average number of participants required. There are multiple benefits of this: if a treatment doesn’t seem to work, ending early means fewer participants receiving a non-working treatment and allows investigators to move on to another possible treatment; if a treatment does seem to work, we can move on to the next phase of testing and get the treatment to more participants sooner. There are also benefits to ending a trial early in terms of financial and time commitments.
In the PTUC, I am involved in the PIPAH trial (Positioning Imatinib for Pulmonary Arterial Hypertension), a phase I/II trial that uses adaptive designs in both phase I and phase II.
Other selected studies: PROTECT-CH (NIHR), a UK-wide clinical trial to identify treatments that can protect care home residents from developing COVID-19.
Other responsibilities: Providing support in all statistical aspects of clinical trial design; Beginner course in R at the MRC Biostatistics Unit.
I am a clinical trial statistician who is strongly committed to providing comprehensive and robust statistical support to my collaborators, to work together to improve the health and well-being of patients and the public. My research focuses on the intersections of trials methodology to continually optimise complex or dynamic interventions, data visualisations, and modelling techniques for longitudinal and survival data. My work at the Papworth Trials Unit Collaboration includes the PIPAH study, (Positioning Imatinib for Pulmonary Arterial Hypertension), which is a two part study with an adaptive dose-finding component.
Originally from Australia, I joined the BSU in February 2022, to work with Dr Sofia Villar, after undertaking doctoral studies at The London School of Hygiene and Tropical Medicine. I have also previously worked at the Pragmatic Clinical Trials Unit and Research Design Service at Queen Mary, University of London, The Nossal Institute for Global Health at the University of Melbourne, and as a Research Methodologist at The Australian Bureau of Statistics.
I am a clinical trial statistician, working in a variety of different clinical research environments and can take on challenging positions involving managing a wide range of complex research areas. My role involves collaboration with clinical investigators to deliver high-impact clinical trials and patient health research studies.
My Research interest in Phase I & II, RCT Phase II & RCT Phase III Clinical Trials, Group sequential/Integrated clinical trial, Multi-Arm Multi-Stage (MAMS) Trials, Retrospective & Perspective, Network Meta analysis and Quality-Of- Life/Supportive Care/Palliative Care clinical Trials. My profession experience in design/monitoring and analysis of clinical trials. My work at the Papworth Trials Unit Collaboration includes the QUACs study (Quality of life after cardiac surgery, a national multicentre observational study).
At the Royal Papworth Hospital, I am helping with developing protocols and research studies, publish scientific papers, lead statistical analysis activities involving multiple clinical research areas, ensured standardization of methods and the quality of the data by assessing and assisting study sites in the design and conduct of the study. Provides support across all statistical tasks during the lifecycle of the research project, from protocol to manuscript publication. Prepares or oversees the preparation of statistical analysis plans (SAP’s), including the development of well-presented mock-up displays for tables, listings, and figures. Additional activities are generation of randomization schedule/specifications, Design/Monitoring/reporting clinical trial, Perform SQC for datasets, QC protocol and QC clinical study report.
Other selected studies: Cross-Sectional Studies, Cohort Studies, Case-Control Studies, Pilot Studies, And Feasibility Studies research conducted in Royal Papworth Hospital.
I am a Statistician based at the MRC Biostatistics Unit within the Design and Analysis of Randomised Trials (DART) theme, and I also work in partnership with the Papworth Trials Unit Collaboration. My main interests lie within applied clinical trial design and analysis.
I am the trial statistician for the NOTACS (Nasal High-Flow Oxygen Therapy After Cardiac Surgery) trial, which is an NIHR funded trial that uses an adaptive trial design. This trial includes an interim sample size re-estimation, which allows us to optimise the sample size and ensure that we are not recruiting too few or too many participants.
Other selected studies: NOMAB, NOTACS aerosol generation sub-study, Rfpb study with Tim Quinell